Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Investing Activities (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Cash from Investing Activities readings, the most recent being -$31.9 million for Q1 2026.

  • On a quarterly basis, Cash from Investing Activities rose 38.08% to -$31.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$169.4 million, a 329.94% decrease, with the full-year FY2025 number at -$189.0 million, down 601.68% from a year prior.
  • Cash from Investing Activities hit -$31.9 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from -$70.8 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $65.3 million in Q4 2024 to a low of -$70.8 million in Q4 2025.
  • Median Cash from Investing Activities over the past 5 years was -$14.9 million (2023), compared with a mean of -$13.0 million.
  • Biggest five-year swings in Cash from Investing Activities: soared 538.38% in 2024 and later crashed 888.58% in 2025.
  • Kiniksa Pharmaceuticals International's Cash from Investing Activities stood at -$42.7 million in 2022, then soared by 65.09% to -$14.9 million in 2023, then soared by 538.38% to $65.3 million in 2024, then tumbled by 208.46% to -$70.8 million in 2025, then soared by 54.93% to -$31.9 million in 2026.
  • The last three reported values for Cash from Investing Activities were -$31.9 million (Q1 2026), -$70.8 million (Q4 2025), and -$62.8 million (Q3 2025) per Business Quant data.